| SC 13G/A | 2020-02-13 | Schall Thomas J. | ChemoCentryx, Inc. | 4,684,775 | 8.0% | EDGAR |
| SC 13G/A | 2020-02-07 | FMR LLC | ChemoCentryx, Inc. | 8,740,285 | 15.0% | EDGAR |
| SC 13G | 2020-02-07 | BlackRock Inc. | ChemoCentryx, Inc. | 4,113,156 | 7.1% | EDGAR |
| SC 13G | 2020-01-10 | Cormorant Asset Management, LP | ChemoCentryx, Inc. | 2,954,814 | - | EDGAR |
| SC 13G | 2019-12-16 | Cormorant Asset Management, LP | ChemoCentryx, Inc. | 3,095,416 | - | EDGAR |
| SC 13G/A | 2019-05-10 | BlackRock Inc. | ChemoCentryx, Inc. | 2,713,033 | 4.7% | EDGAR |
| SC 13G/A | 2019-04-15 | BIO-TECHNE Corp | ChemoCentryx, Inc. | 3,987,654 | 7.2% | EDGAR |
| SC 13G | 2019-04-10 | FMR LLC | ChemoCentryx, Inc. | 5,774,432 | 11.0% | EDGAR |
| SC 13G/A | 2019-02-14 | BIOTECHNOLOGY VALUE FUND L P | ChemoCentryx, Inc. | 2,172,757 | 4.3% | EDGAR |
| SC 13G/A | 2019-02-14 | BIOTECHNOLOGY VALUE FUND L P | ChemoCentryx, Inc. | 1,512,463 | 3.0% | EDGAR |
| SC 13G/A | 2019-02-13 | Schall Thomas J. | ChemoCentryx, Inc. | 4,834,663 | 9.1% | EDGAR |
| SC 13G/A | 2019-02-04 | BlackRock Inc. | ChemoCentryx, Inc. | 2,729,701 | 5.4% | EDGAR |
| SC 13D | 2018-11-02 | Vifor (International) Ltd | ChemoCentryx, Inc. | 7,343,492 | 14.6% | EDGAR |
| SC 13D/A | 2018-10-18 | GLAXOSMITHKLINE PLC | ChemoCentryx, Inc. | 0 | 0.0% | EDGAR |
| SC 13D/A | 2018-09-18 | GLAXOSMITHKLINE PLC | ChemoCentryx, Inc. | 7,343,492 | 14.6% | EDGAR |
| SC 13G/A | 2018-02-14 | BIOTECHNOLOGY VALUE FUND L P | ChemoCentryx, Inc. | 2,439,556 | 5.0% | EDGAR |
| SC 13G/A | 2018-02-13 | Schall Thomas J. | ChemoCentryx, Inc. | 4,857,630 | 9.4% | EDGAR |
| SC 13G | 2018-02-01 | BlackRock Inc. | ChemoCentryx, Inc. | 2,742,607 | 5.6% | EDGAR |
| SC 13G/A | 2017-02-14 | BIOTECHNOLOGY VALUE FUND L P | ChemoCentryx, Inc. | 2,472,477 | 5.2% | EDGAR |
| SC 13G/A | 2017-02-13 | Schall Thomas J. | ChemoCentryx, Inc. | 4,417,876 | 8.8% | EDGAR |